Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2012 by University of Aarhus
Arla Foods
Information provided by (Responsible Party):
University of Aarhus Identifier:
First received: February 13, 2012
Last updated: December 14, 2012
Last verified: December 2012

Casein glycomacropeptide (CGMP) has anti-inflammatory properties in experimental rodent colitis and using human in vitro inflammation models. Its use as a food ingredient has proven safe and with no influence on dietary intake. We hypothesize that orally administered CGMP has a beneficial effect comparable to that of mesalazine in active distal ulcerative colitis.

Condition Intervention Phase
Colitis, Ulcerative
Inflammatory Bowel Diseases
Drug: CGMP protein
Drug: Maximal oral 5ASA
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)

Resource links provided by NLM:

Further study details as provided by University of Aarhus:

Primary Outcome Measures:
  • Fecal calprotectin reduction [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    Relative reduction in fecal calprotectin measured before and after 4 weeks treatment: DIFF = ((FCALPbefore - FCALPafter)/FCALPbefore)*100 percent

Secondary Outcome Measures:
  • Clinical Activity Index [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    Simple Colitis Activity Index (range 0-20)

  • Quality of life [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    Quality of life measured yb Short Health Scale (4 items ranged 0-10, total range 0-40)

  • Endoscopic Mayo score [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    Grade of inflammation (range 0-3) in rectum according to Mayo score, visually judged during endoscopy

  • Serial fecal calprotectin [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    fecal calprotectin week 0-2-4-6-8

Estimated Enrollment: 40
Study Start Date: January 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CGMP protein
Casein glycomacropeptide 30 gram/day, unchanged prophylactic 5ASA dose
Drug: CGMP protein
Casein glycomacropeptide purified powder dissolved in 300 ML water once daily
Other Name: Casein glycomacropeptide
Active Comparator: Standard oral 5ASA maximal dose
Increase from prophylactic dose 5ASA (mesalazine) to maximal oral dose, i.e. 4800 grams of mesalazine (Asacol/Mezavant)
Drug: Maximal oral 5ASA
4800 grams/day of Mesalazine (Asacol/Mezavant)
Other Names:
  • Asacol
  • Mezavant
  • Mesalazine

Detailed Description:

GCMP has mainly been used as food additive in patients with specific dietary needs, i.e. in infant formulas, adipositas, or in patient with phenylketonuria. Due to its antiinflammatory properties we hypothesize that it may be used alone or along with conventional therapy in inflammatory diseases such as ulcerative colitis.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years or more
  • Diagnosed ulcerative colitis
  • Signs of clinical activity with SCCAI of 3 or more
  • Extension more than 10 cm and no more than 40 cm from anus

Exclusion Criteria:

  • Rectal temperature more than 38 degrees Celcius
  • Diagnosed celiac disease or lactose intolerance
  • Unable to speak or understand Danish
  • Prior biologics or systemic steroids 4 weeks up to inclusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01534312

Contact: Jørgen S Agnholt, MD PhD +4589493895
Contact: Christian L Hvas, MD PhD +4589493895

Department of medicine V (Hepatology and Gastroenterology) Recruiting
Aarhus C, Denmark, 8000
Contact: Jørgen S Agnholt, MD PhD    +4589493895   
Contact: Christian L Hvas, MD PhD    +4578463895   
Principal Investigator: Jørgen S Agnholt, MD PhD         
Sub-Investigator: Christian L Hvas, MD PhD         
Sub-Investigator: Jens F Dahlerup, MD DMSci         
Sub-Investigator: Lisbet A Christensen, MD DMSci         
Sub-Investigator: Anders K Dige, MD         
Sponsors and Collaborators
University of Aarhus
Arla Foods
Study Chair: Hendrik Vilstrup, Professor Professor, University of Aarhus
  More Information

No publications provided

Responsible Party: University of Aarhus Identifier: NCT01534312     History of Changes
Other Study ID Numbers: CGMP in UC
Study First Received: February 13, 2012
Last Updated: December 14, 2012
Health Authority: Denmark: The Regional Committee on Biomedical Research Ethics

Keywords provided by University of Aarhus:
Dietary proteins

Additional relevant MeSH terms:
Colitis, Ulcerative
Inflammatory Bowel Diseases
Intestinal Diseases
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Pathologic Processes
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Chelating Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Sequestering Agents
Therapeutic Uses processed this record on November 19, 2014